Eric Davis, Baseball Star, Leads New Colon Cancer Awareness Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 5
Volume 8
Issue 5

WASHINGTON-Baseball star and colon cancer survivor Eric Davis has launched “Score Against Colon Cancer,” a public awareness and screening campaign that will capitalize on the St. Louis Cardinals slugger’s celebrity status and personal experience.

WASHINGTON—Baseball star and colon cancer survivor Eric Davis has launched “Score Against Colon Cancer,” a public awareness and screening campaign that will capitalize on the St. Louis Cardinals slugger’s celebrity status and personal experience.

The “Score” campaign is an educational effort of the Eric Davis Foundation, Bristol-Myers Squibb Oncology, the American College of Gastroenterology, Cancer Care, Inc., and the Lexon Group, which is developing a blood serum test for colon cancer that uses the TGFB4 (ebaf) protein marker.

Mr. Davis leads the campaign, which includes a 60-second TV public service ad in which he describes his reaction to being diagnosed with colon cancer and urges men age 50 and over and those under age 50 with a family history of cancer to get screened. He will also make 21 appearances at hospitals and cancer centers in 17 major league cities during the course of the 1999 baseball season to publicize the need for screening.

The campaign offers educational information through its toll-free number (1-877-SCORE-123) and its website (www.scorecrc.com). Individuals can ask to receive colon cancer educational material or to speak directly to a certified oncology counselor.

“Score Against Colon Cancer is something I truly believe in,” Mr. Davis said at a press conference to announce the campaign. “I’ve lived it. I know. I’m here to tell you that colon cancer can be beaten.”

Mr. Davis came out of retirement in 1997 at age 35 to play with the Baltimore Orioles. He soon developed abdominal pain, fatigue, and weight loss, all of which he initially attributed to “the grueling aspects of being a professional athlete,” he said. But on June 9, he entered Johns Hopkins University Hospital, where he was diagnosed with colon cancer. Surgeons removed a tumor “the size of a baseball,” he said. He returned to the Orioles roster in 1998, and in the final month of the season batted around .400. He signed with St. Louis in the off-season.

Ironically, Mr. Davis was soon given the opportunity to urge his childhood friend and fellow ballplayer, Darryl Strawberry, to have suspicious symptoms examined. Mr. Strawberry was also diagnosed with colorectal cancer, which was treated with surgery and chemotherapy.

During his chemotherapy treatments at Johns Hopkins, Mr. Davis said he visited with cancer patients, including those terminally ill. It was then that he decided to set up a foundation to raise money for colon cancer and pediatric cancer. “The important thing, I felt, was to create an awareness campaign,” he said.

Related Videos
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content